Christopher Capelli
Founder bei SOLITON, INC.
Profil
Christopher Capelli is the founder of Soliton, Inc. (Texas) and Biointerface Technologies, Inc. which were founded in 2021 and 1987 respectively.
At Soliton, Inc. (Texas), he holds the title of Vice Chairman & Chief Science Officer.
Currently, Dr. Capelli is an Independent Director at Autonomix Medical, Inc. since 2023.
In the past, he worked as the Director-Office of Technology Management at the University of Pittsburgh from 2001 to 2005 and as the Vice President at The University of Texas at Austin from 2005 to 2014.
Dr. Capelli's education includes an undergraduate degree from Massachusetts Institute of Technology and a doctorate from the University of Wisconsin School of Medicine & Public Health.
Aktive Positionen von Christopher Capelli
| Unternehmen | Position | Beginn |
|---|---|---|
| SOLITON, INC. | Founder | 01.02.2021 |
| AUTONOMIX MEDICAL, INC. | Director/Board Member | 01.09.2023 |
Ehemalige bekannte Positionen von Christopher Capelli
| Unternehmen | Position | Ende |
|---|---|---|
| The University of Texas at Austin | Corporate Officer/Principal | 01.08.2014 |
| University of Pittsburgh | Corporate Officer/Principal | 01.02.2005 |
| Biointerface Technologies, Inc. | Founder | 01.01.1998 |
Ausbildung von Christopher Capelli
| Massachusetts Institute of Technology | Undergraduate Degree |
| University of Wisconsin School of Medicine & Public Health | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| AUTONOMIX MEDICAL, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Soliton, Inc. (Texas)
 Soliton, Inc. (Texas) Medical SpecialtiesHealth Technology Soliton, Inc. is a medical development company, which engages in the development of healthcare technological devices for medical and cosmetic treatments. Its technology platform include Rapid Acoustic Pulse, a device uses rapid pulses of designed acoustic shockwaves to disrupt cellular structures in the dermal and subdermal tissue. The firm is also in the pre-revenue stage with its first products being developed for the removal of tattoos and the reduction of cellulite. The company was founded by Walter V. Klemp and Christopher Capelli on March 27, 2012 and is headquartered in Houston, TX. | Health Technology |
| Biointerface Technologies, Inc. |
